Cargando...
The hepatitis C genotype 1 paradox: Cost per treatment is increasing, but cost per cure is decreasing
Significant attention has been focused on the perceived increase in the cost of antiviral treatment for hepatitis C genotype 1 infection since the approval of the first direct-acting antiviral agents in 2011. Using Canadian list prices, the present analysis points out a paradox: while the cost per a...
Guardado en:
| Publicado en: | Can J Gastroenterol Hepatol |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Pulsus Group Inc
2015
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4334067/ https://ncbi.nlm.nih.gov/pubmed/25706574 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|